Core Viewpoint - Altria Group is considered a strong buy-and-hold investment despite controversies surrounding its tobacco business, with a history of benefiting long-term investors [1]. Financial Performance - Altria shares have generated annualized returns of nearly 18% over the past five years, outperforming the S&P 500's annualized total returns of around 13% during the same period [2]. - The company has a market capitalization of $112 billion, with a current stock price of $66.54 and a dividend yield of 6.25% [3]. - Altria's total returns since February 2021 have reached 128.6%, significantly higher than the S&P 500's 85.8%, Coca-Cola's 81.7%, and Procter & Gamble's 41.6% [6]. Dividend Growth - Altria is classified as a "Dividend King," having over 50 years of consecutive dividend growth, with a forward dividend yield of 6.3% [5]. - The company has maintained steady earnings and dividend growth in the low single-digit range, primarily through price increases on smokeable products [10]. Market Position and Challenges - Altria generates approximately 88% of its total net revenue from smokeable products, lagging behind competitors like Philip Morris International, which derives around 41.5% of its revenue from smoke-free products [7][8]. - Past investments in smoke-free products, such as Juul Labs and Njoy, have resulted in significant impairment losses and legal challenges [9]. Future Outlook - Altria's modest earnings growth is expected to support its 6.3% dividend, positioning the company for solid returns in the future [11]. - The potential for valuation expansion exists, as Altria currently trades at 12 times forward earnings compared to Philip Morris International's 22 times [13]. - The company could enhance its nicotine pouch business through acquisitions, which may lead to stronger earnings growth and improved stock performance [12].

Core Viewpoint - Constellation Brands and Altria are both considered stable blue chip stocks, but Altria has outperformed Constellation significantly over the past three years, raising questions about future investment potential [1][2]. Constellation Brands - Constellation Brands generates most of its revenue from its beer business, with popular brands like Modelo and Corona, and a smaller portion from wine and spirits [4]. - The company faces three major challenges: declining beer consumption among younger consumers, decreasing sales of lower-end wines, and increased costs due to tariffs on imported Mexican beers [5][6]. - Analysts expect Constellation's revenue to decline from $10.2 billion in 2024 to $9.9 billion in 2027, while its earnings per share (EPS) is projected to grow at a compound annual growth rate (CAGR) of 7% [8]. - Despite a low valuation at 14 times forward earnings and a forward yield of 2.5%, the lack of near-term catalysts makes it an unappealing investment [9]. Altria - Altria primarily generates revenue from its Marlboro cigarettes and has a strong domestic focus, which protects it from tariffs and foreign-exchange issues [10][11]. - The company has been countering declining smoking rates by raising cigarette prices, cutting costs, and expanding its smokeless product portfolio through investments and acquisitions [12]. - Following a setback with its investment in Juul, Altria acquired Njoy for $2.8 billion in 2023, which is expected to boost EPS starting in 2026 [13]. - Analysts predict Altria's revenue will dip slightly from $20.4 billion in 2024 to $20.2 billion in 2027, but its EPS is expected to grow at a steady CAGR of 5% from 2025 to 2027 [14][15]. - Altria's stock is considered cheap at 12 times forward earnings, with a substantial forward yield of nearly 7%, making it a more stable investment compared to Constellation [15]. Investment Recommendation - Altria is viewed as the better investment option due to its more stable business model, larger dividend, and lower valuation multiple compared to Constellation Brands [16].

Core Viewpoint - Altria remains an attractive investment for income investors due to its long history of dividend increases and its current high dividend yield of 7% [1][14] Company Strategy - Altria has faced challenges over the past decade due to declining smoking rates and strategic missteps, including a $12 billion investment in Juul and a failed investment in Cronos Group [5] - The company has shifted focus to smoke-free products, selling the rights to market Iqos back to Philip Morris International and investing in Njoy, which has received FDA marketing authorization for its pod-based e-vapor product [6][8] - Altria's next-gen portfolio includes on!, an oral nicotine pouch, and a new heated tobacco product called Ploom, developed in partnership with JT Group [7] Market Performance - Njoy's consumables saw a 15.3% increase to 12.8 million units, and device shipments rose 22.2% to 1.1 million, with retail market share nearly doubling to 6.4% [8] - Despite Njoy's growth, cigarettes still account for the majority of Altria's revenue, with volume sales declining from 76.4 million in 2023 to 68.6 million in 2024, while smokeable products represented 88% of revenue in 2024 [9] Future Goals - Altria aims for a mid-single digits adjusted earnings per share (EPS) compound annual growth rate (CAGR) off $4.84 in 2022, with adjusted EPS rising 3.4% to $5.12 in 2024, resulting in a 2.9% CAGR over the last two years [10] - The company plans to increase its dividend by mid-single digits annually, following a 4.1% increase in 2024, and targets a debt-to-EBITDA ratio of 2, currently at 2.1 [11] - Altria expects to maintain an adjusted operating margin of at least 60% through 2028, although it has struggled to meet growth targets and has adjusted its expectations for Njoy's cash flow contributions [12] Investment Outlook - Altria's stock trades at a price-to-earnings ratio of 12, with a 7% dividend yield, indicating potential for success even if not all 2028 goals are met [13] - In the current economic climate, Altria is positioned to potentially outperform the S&P 500, benefiting from its status in the consumer staples sector and the consistent demand for its products [14] - Overall, despite declining cigarette consumption, Altria is expected to be in a better position three years from now [15]

Core Viewpoint - The article compares Altria and Philip Morris International, highlighting their differing business models, financial performance, and growth prospects in the tobacco industry, particularly in the context of their transitions to smoke-free products. Business Model Comparison - Altria and Philip Morris, despite sharing cigarette brands, have different business models, with Altria focusing on the U.S. market and Philip Morris on international markets [2][3] - Philip Morris has successfully developed next-generation products like Iqos and Zyn, gaining significant market share, while Altria has struggled with its investments in Juul and cannabis [4][5][6] Financial Performance - In 2024, Altria's revenue declined by 1.9% to $24 billion, primarily due to a 10.2% drop in cigarette shipment volume, although it maintained a high adjusted operating margin of 61.2% [8][9] - Philip Morris reported a 7.7% increase in revenue to $37.9 billion, with a 0.6% rise in international cigarette volume and a 16% increase in operating income [9] Dividend and Valuation - Altria offers a dividend yield of 7% and trades at a price-to-earnings ratio of 11.3, maintaining a strong reputation as a dividend payer [10][11] - Philip Morris has a lower dividend yield of 3.5% but a higher P/E ratio of 22, reflecting its faster growth and success in next-gen products [11] Growth Prospects - Altria is beginning to see growth from its investment in Njoy, but it continues to face revenue losses and challenges in its core cigarette business [12] - Philip Morris is experiencing growth in both its next-gen products and its cigarette business, indicating a more favorable long-term growth trajectory [12][13]